6533b7d9fe1ef96bd126bfe4

RESEARCH PRODUCT

Special Situations in APL

Gloria IacoboniMiguel A. SanzMiguel A. SanzMassimo Breccia

subject

OncologyAcute promyelocytic leukemiamedicine.medical_specialtybusiness.industryGenetic variantsmedicine.diseaseLeukemiachemistry.chemical_compoundTherapeutic approachchemistryOlder patientsInternal medicinemedicineHematologic malignancyTreatment strategyArsenic trioxidebusiness

description

The introduction of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) as the mainstay therapy of acute promyelocytic leukemia (APL) has drastically changed the outcome of this hematologic malignancy into one of the first to receive a targeted treatment. Using frontline treatment strategies including these agents in combination with standard cytotoxic drugs has provided outstanding therapeutic results in most patients. In spite of the achievement of brilliant results in the majority of patients, some special situations still require the implementation of changes from the conventional therapeutic approach. In this chapter, we will review and discuss the management of APL in older and frail patients, children and pregnant women, as well as those with therapy-related leukemia, extramedullary relapse, and the extremely rare situation of the genetic variants.

yearjournalcountryeditionlanguage
2017-09-26
https://doi.org/10.1007/978-3-319-64257-4_16